Source: Annual Congress 2003 - Lung cancer biology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
J. A. Huang, T. L. Wang, Y. M. Zhuang, Y. B. Zhu, T. Gu, X. G. Zhang (Suzhou, China). The role of CD40 molecule in human lung cancer and its application in immunotherapy. Eur Respir J 2003; 22: Suppl. 45, 1338

Member's Comments

No comment yet.

Related content which might interest you: The clinical significance of CD40 molecule expressed on human lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 394s Year: 2003 The effect of adhesion molecule CEACAM1 and chemokine receptor CXCR4 expression on prognosis of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005 Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018 Year: 2019 Toll-like receptor 3 is up-regulated and enhances anti-proliferative function in human non-small cell lung cancer Source: Annual Congress 2008 - Lung cancer and other malignant diseases involving the lungs Year: 2008 Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10 Source: Eur Respir J 2007; 30: 608-610 Year: 2007 Association of antiPD1 immunotherapy with immunogenic cell death-inducing chemotherapy in a murine model of squamous cell lung cancer Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 Microbial analysis in lung cancer according to PD-L1 level and immunotherapy response Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker Source: International Congress 2019 – Biology of lung cancer Year: 2019 Prognostic and potential therapeutic impact of prostate specific membrane antigen expression in non-small cell lung cancer Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Interleukin-17 enhances the net angiogenic potential and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis Source: Eur Respir J 2004; 24: Suppl. 48, 79s Year: 2004 CAR T-cell therapy for lung cancer Source: International Congress 2017 – A novel approach to lung cancer Year: 2017 Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer> Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021 The expression of PD-L1 on the lung cancer cell and its role in T cell anergy Source: Eur Respir J 2007; 30: Suppl. 51, 289s Year: 2007 The role of STAT3 in T-cell responses during the development of NSCLC Source: International Congress 2017 – Lung cancer - basic science: the latest results from the bench Year: 2017 XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Ras peptide-specific vaccination in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 The role of immunotherapy Source: Annual Congress 2006 - PG7 - Paediatric respiratory medicine: allergy for paediatric pulmonologists Year: 2006 Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021